Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, . Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.
   PubMed Web of Science ®Google Scholar
• Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, MacKenzie R, . Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 2004;198:722–31.
   PubMed Web of Science ®Google Scholar
• Conlon K.C, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273–9.
   PubMedGoogle Scholar
• Willett CG, Czito BG, Bendell JC. Cancer of the pancreas. Perez CA, Brady LW. Principles and practice of radiation oncology. 5th. Philadelphia: Lippincott; 2008. 1338–9.
   Google Scholar
• Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, . Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56–61.
   PubMed Web of Science ®Google Scholar
• Tepper J, Nardi G, Suitt H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976;37:1519–24.
   Google Scholar
• Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer—local or hepatic? Hepatogastroenterology 1993;40:384–7.
   PubMedGoogle Scholar
• Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205–8.
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, . Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–82.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, . A randomized trial of hemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
   PubMed Web of Science ®Google Scholar
• Valentini V, Morganti AG, Macchia G, Mantini G, Mattiucci GC, Brizi MG, . Intraoperative radiation therapy in resected pancreatic carcinoma: Long-term analysis. Int J Radiat Oncol Biol Phys 2008;70:1094–9.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind Ch.. TNM Classification of malignant tumors, 5th. New York: John Wiley & Sons, Inc.; 1997.
   Google Scholar
• Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, . Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Up-regulation of thymidine phosphorylase. Cancer J 2007;13:247–56.
   PubMed Web of Science ®Google Scholar
• Withers HR. Biological basis of radiation therapy. Perez CA, Brady LW. Principle and practice of radiation oncology. Philadelphia: Lippincott; 1992. 64–9.
   Google Scholar
• Withers HR. Radiation biology and treatment options in radiation oncology. Cancer Res 1999;59:1676–84.
   Web of Science ®Google Scholar
• Buskirk SJ, Gunderson LL, Schild SE, Bender CE, Williams HJ Jr, McIlrath DC, . Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. Ann Surg 1992;215:125–31.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6.
   PubMed Web of Science ®Google Scholar
• McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, . Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202–8.
   PubMed Web of Science ®Google Scholar
• Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F, . 5-FU-based chemoradiation in unresectable pancreatic carcinoma: A phase II dose escalation study. Int J Radiat Oncol Biol Phys 2004;59:1454–60.
   PubMed Web of Science ®Google Scholar
• Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, . Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004;59:1461–7.
   PubMed Web of Science ®Google Scholar
• Feyer PCh, Maranzano E, Molassiotis A, Clark-Snow RA, Roila F, Warr D, . Radiotherapy-induced nausea and vomiting (RINV): Antiemetic guidelines. Support Care Cancer 2005;13:122–8.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267–77.
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, . Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008;299:1019–26.
   PubMed Web of Science ®Google Scholar